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Chagas disease (CD) is a neglected tropical disease caused by the hemo!agellate Try-
panosoma cruzi.
Although endemic in the rural Latin America, par-
ticularly in the Gran Chaco area of Bolivia, Para-
guay and Argentina, its epidemiology changed in 
the last few decades due to the mass migration 
towards the United States, Europe and Italy par-
ticularly [1-2]. Among all, Bolivians are the most 
affected Latin Americans [3]. In Bergamo prov-
ince, Northern Italy, the main Bolivian communi-
ty in Italy is currently present, representing about 
43% of all Bolivians resident in Italy. Considering 
undocumented people, about 10000 Bolivians are 
living in Bergamo’s province, out of 1.1 million. 
A previous retrospective (2012-2013) cohort study 
on 1305 Latin American residents in Bergamo’s 
province showed T. cruzi seroprevalence in 17% 
of people [4]. More recent (2013-2016) data of T. 
cruzi infection in 561 Bolivians residents in Ber-
gamo’s province con"rm the prevalence of 19% 
(unpublished data). In most part of cases CD is a 
silent disease; the chronic form, around a third of 
cases, evolves to heart or digestive disease, with 
important sequelae [5].
Children and pregnant women represent the most 
vulnerable population in the epidemiological chain 
of CD, also in non-endemic areas. Chronic CD, 
indeed, has appeared also in non-endemic areas 
in migrants, as it was for the acute forms mainly 
caused by vertical transmission during the period 
immediately before and after delivery [6].
Due to low and intermittent parasitemia, diagno-
sis of chronic CD is mainly performed through 
serological tests, using a whole-parasite antigen 
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Chagas disease (CD) is an uncommon disease in Europe. 
Its epidemiology has changed because of mass migration 
from Latin America to Europe. Herein we describe a 
congenital case of CD in a Bolivian newborn in Bergamo, 
the main city of residence for the Bolivian community 
in Italy. At delivery, serological analyses evidenced IgG 
antibodies against Trypanosoma cruzi both in the child and 
mother, as expected. Hemoscopic analyses on peripheral 
blood were repeatedly negative during the "rst months of 
life. Eventually, thanks to T. cruzi Real Time polymerase 
chain reaction (RT-PCR) positivity on peripheral blood 
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and development of progressive anemia in the following 
weeks, congenital Chagas disease was diagnosed and 
benznidazole-based therapy started. A progressive 
antibodies’ index decrease was observed till negativity 
(306 days apart). RT-PCR was negative at the end of 
treatment. Our case is instructive and management of 
congenital CD is discussed from the perspective of a non-
endemic country.
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or recombinant antigens [7]. The new generation 
tests stress the optimal characteristics in terms of 
sensitivity and speci"city, probably linked to the 
greater T. cruzi protein differences, and their ge-
netic diversity [8].
? CASE REPORT
N.M.R. was born by spontaneous vaginal deliv-
ery at 34 week + 4 days (weight 5,99 lbs) on 14th 
March 2015, from a Bolivian mother. She tested 
positive to T. cruzi serology [index 10.9 (cutoff 
=1.0)] just before delivery by chemiluminescent 
microparticle immunoassay (CMIA) from recom-
binant antigens (Architect Chagas -Abbott Labo-
ratories, Wiesbaden, Germany). The evidence of 
asymptomatic hypoglycemia and hyperbilirubin-
emia in the "rst hours of the child’s life, consid-
ering the maternal serological reactivity, leads to 
in-depth diagnosis aimed at excluding a possible 
congenital CD. 
For these reasons, direct parasitological analy-
ses were "rst carried out to search for T. cruzi in 
peripheral blood (thin blood "lm, thick blood 
smears and buffy coat leukocyte) with negative 
results. Moreover, speci"c IgG antibodies were 
searched in child’s serum samples by CMIA test 
from recombinant antigens. This analysis proved 
positive [index 11.27 (cutoff =1.0)], just like the 
one on the mother’s serum.
This positive reaction was further con"rmed by 
LineBlot procedure (NovaLine Chagas IgG - No-
vaTec Immundiagnostica GmbH - Germany) 
based on the recombinant TcF-Protein.
In the "rst four weeks of life, the baby suffered 
from frequent episodes of apnoea and hemolytic 
anemia (lowest haemoglobin level, 76 g/L), but 
direct Coombs test was negative, as other TORCH 
complex infections. Finally, he was again hospi-
talized one month after the birth because of his 
unclear apnoea and anemia. 
Direct parasitological analyses on peripheral 
blood (with negative results) and reactivity to T. 
cruzi (CMIA index 8,14) were once more repeat-
ed before a transfusion of concentrated red cells. 
Echocardiography, brain and abdominal ultra-
sounds were normal. 
On day 32 a peripheral blood sample was taken 
in EDTA and the execution of a Real-Time PCR 
(T. cruzi genesig® Advanced Kit, PrimerDesignTM, 
UK) was requested: the test showed a “Weakly 
Positive” result.
In the following weeks the progressive and rap-
id anemization (Hb 76 ? 62 g/L), in spite of the 
good general conditions with regular growth and 
advancement without evident etiological agent of 
disease (negativity in Coombs test, hemoglobin 
electrophoresis, osmotic resistance, G6PD de"-
ciency) lead to a further hemotransfusional ther-
apy.
Two further samples, drawn respectively on day 
68 and 88, lead to a Real-Time PCR “Positive” re-
sults and con"rmed the presence of circulating T. 
cruzi DNA.
Therefore, the diagnosis of T. cruzi congenital in-
fection has been made, even if the only clinical ev-
idences were recurrent anemia, prematurity and 
low birth weight.
On day 110 the pharmacological treatment based 
Figure 1 - Chagas IgG trend.
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on benznidazole (Abarax, Laboratorio ELEA 
S.A.C.I.F. y A., Buenos Aires, Argentina) was 
started (4.85 mg/kg/die for 7 days; then, 8.5 mg/
kg/die for 7 weeks). 
The direct hemoscopic analyses repeated lat-
er were always negative and serological tests 
showed a reduction of the index from 6.22 to 5,57 
and "nally to 4.39.
On day 151, clinical analyses were indicative of 
good general conditions. The patient was vigilant 
and responsive, with regular trophism, autono-
mous breath, valid and pure heart tone, auton-
omous pauses, manageable !at abdomen. Liver 
and spleen were within the limits and the lym-
phatic apparatus was unharmed. The pharma-
cologic therapy was maintained till day 172, and 
then suspended. 
On day 185 a reduction in the anemia picture 
frame (Hb 11.5 g/L) was observed. The Real-Time 
PCR test showed no evidence of T. cruzi DNA in 
the peripheral blood, the hemoscopic checks were 
negative and the antibodies in steep decrease (in-
dex 1,80).
Finally, on day 306 the serological analysis turned 
negative (index 0,63), and this result was recon-
"rmed by the 30-month-later follow-up, as sum-
marized in Figure 1. 
At the end of the breast-feeding period, the child’s 
mother was treated with benznidazole, for two 
months.
? DISCUSSION 
CD currently represents an emerging public 
health problem, particularly in pregnant women 
and newborns. Not-endemic countries and Italy 
do not represent an exception. 
In Bergamo, where the main Bolivian commu-
nity in Italy resides, a protocol has been agreed 
with the Public Health Authorities to monitor the 
speci"c antibodies in Bolivian women within the 
third month of pregnancy or at delivery, to per-
form hemoscopic check in the newborn’s periph-
eral blood in case of maternal seropositivity, and 
to make a comparison between the mother’s anti-
body index and the newborn’s one at least for one 
year after the birth and in any case till negativity. 
The cure assessment is evaluated through parasi-
tological and serological methods [9, 10].
Even if no congenital CD cases are reported in 
Italian literature, it remains a diagnostic chal-
lenge, particularly if direct parasitological anal-
yses carried out at delivery to search for T. cruzi 
in peripheral blood (thin blood "lm, thick blood 
smears and buffy coat leukocyte) are negative, 
clinical condition of the newborn are not highly 
suggestive for CD, maternal and child’s serolog-
ical index are similar, and PCR is not available. 
The decrease of antibody index highlighted by 
the use of CMIA test (sensitivity 100%, speci"city 
97.6%) is comforting because it allows us to be-
lieve that the infectious process which has affect-
ed the child is evolving in a favorable way [11]. 
Abras et al. report a continuous decreasing trend 
of passive IgG antibodies in 12-months in non-in-
fected newborns; however, the antibody decline 
shows up after the start of the treatment in CD 
cases [12]. 
Considering that antibodies disappear at different 
time scales according to the phase of the disease, 
the age of patients and the genetic variability of T. 
cruzi, PCR can be a helpful tool to monitor acute 
forms of the disease; however, due to the intermit-
tent and low parasitemia in the post-acute phase 
of CD, a negative PCR result does not necessarily 
suggest absolute absence of the parasite [13, 14]. 
The evidence of PCR tests which become pos-
itive once more, indeed, permits to record ther-
apeutic failures after the treatment in the recent 
trials, probably due to a poor effectiveness of the 
benznidazole to penetrate into the infected tissues 
or to the existence of T. cruzi strain resistant to the 
currently used drugs [15, 16].
A different strategy is suggested for the diagnosis 
of congenital CD: polymerase chain reaction (PCR) 
could be proposed to con"rm the maternal sero-
logical reactivity, and for newborns direct parasi-
tological exams and PCR represent important tools 
in the "rst weeks of life, even if a positivity at that 
time could be considered as a maternal contami-
nation, particularly in asymptomatic children, and 
serology is used after the "rst six months of life 
when maternal antibodies are lost [12].
In conclusion, we believe that active screening 
for T. cruzi infection in at risk pregnant women 
is of primary importance to guide newborn (and 
mother) follow-up: TORCH complex should not 
be regarded as a "x and limited disease complex, 
especially in this era of globalization. Moreover, 
all newborns, even if asymptomatic, whose moth-
ers are of Latin American origin should perform 
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active clinical and microbiological check-ups. 
Those diagnosed of congenital CD must be fol-
lowed with appropriate laboratory tests, includ-
ing RT-PCR, every six months for at least the "rst 
few years of life. 
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